You are here

New therapeutics

The current status for Biosimilars is discussed in two articles, one by Kay et al. providing consensus-based recommendations from EULAR, the other by Cohen et al. providing a comprehensive overview of the approval of five TNF inhibitors and the status of clinical development for additional TNF-inhibitors, as well as rituximab, abatacept and tocilizumab. Importantly, no issues have surfaced based on switching studies in several countries and post-marketing surveillance. Worries about immunogenicity, new safety issues, and loss of efficacy have not materialized. Thus, it is possible that this initial experience and favorable pricing will enable more patients to benefit from these powerful, joint-sparing therapies.

This topic is also discussed in the following three videos:


Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre.

Clinical Rheumatology

Journal cover clinical Rheumatoloy - Elsevier Resource Centre

Spread the word

If you like this resource centre, please share it.